Insilico Medicine is a biotech company that uses AI in drug discovery and development. They are developing drugs for various diseases and have a focus on drug repurposing. Insilico Medicine uses AI platforms like PandaOmics, Chemistry42, and inClinico. They have collaborated with companies like GSK, Pfizer, and Novo Nordisk. The company has a high valuation and has raised significant funding. They also have an Intelligent Robotics Drug Discovery Laboratory. The use of AI in drug discovery offers advantages in efficiency and cost reduction. The study published by Insilico Medicine in Nature Biotechnology is significant in demonstrating the translation of AI-predicted findings into clinical trials. The Vice President of Business Development at Insilico Medicine is Keith Mikule.
